A new treatment for hallucinations and delusions in patients with Parkinson’s disease

Hallucinations and delusions are not only a side effect of treatment of Parkinson’s disease but a symptom of the disease itself that appear up to 50% of patients. Symptoms often worsen with disease progression distressing to the patient and to the accompanying concerned and family. Among the risk factors is that dementia-related hallucinations. Similarly if a patient starts with hallucinations, we will be closely monitored to promptly detect the onset of cognitive impairment. We should routinely ask to patients and families about their presence or detection. Hallucinations although initially they may be visual could sometimes be auditory, visual, even see insects like syndrome Ekman, olfactory or tactile. Then appear you should consult a neurologist to look for the causes, review the treatment and remove those drugs that can produce, as some tricyclic antidepressant, reduce in a manner consistent treatment of the disease, and if not improve associate anticholinesterase and neuroleptics atypical. Reducing the Parkinson’s disease specific treatment in an orderly manner and by removing drugs that are less effective and may have greater potential facilitator. Neuroleptic drugs are effective but can sometimes worsen parkinsonism or accompanied by side effects, so we have to supervised its use in patients. When we analyze the studies are scarce and not very strong, but individually evidence is an appropriate remedy. New hope in treatment is track 5-HT2A, as the pimavanserin that appears to show a good symptom control without deterioration of Parkinson’s disease. A priori seems to have few adverse effects